Search results
Results From The WOW.Com Content Network
(Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
By Ludwig Burger. FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business.
By Ludwig Burger. FRANKFURT (Reuters) - Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart ...
Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Novartis turned $12.5 billion worth of revenue into per-share earnings of $1.97 in Q2, topping expectations for a profit of $1.89 per share on sales of a little less than $12.4 billion. Better ...
He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables.
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last...
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.